These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22419388)

  • 1. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.
    Piechocki MP; Wu GS; Jones RF; Jacob JB; Gibson H; Ethier SP; Abrams J; Yagita H; Venuprasad K; Wei WZ
    Int J Cancer; 2012 Dec; 131(11):2562-72. PubMed ID: 22419388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
    Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
    Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
    Fancy RM; Kim H; Napier T; Buchsbaum DJ; Zinn KR; Song Y
    J Cell Biochem; 2018 Jul; 119(7):6216-6230. PubMed ID: 29663486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
    Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
    Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
    Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
    MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis.
    Herbeuval JP; Grivel JC; Boasso A; Hardy AW; Chougnet C; Dolan MJ; Yagita H; Lifson JD; Shearer GM
    Blood; 2005 Nov; 106(10):3524-31. PubMed ID: 16046522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
    Chen JJ; Chou CW; Chang YF; Chen CC
    J Immunol; 2008 Jun; 180(12):8030-9. PubMed ID: 18523266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Importin β1 Augments the Anticancer Effect of Agonistic Anti-Death Receptor 5 Antibody in TRAIL-resistant Tumor Cells.
    Kojima Y; Nishina T; Nakano H; Okumura K; Takeda K
    Mol Cancer Ther; 2020 May; 19(5):1123-1133. PubMed ID: 32156787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
    Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
    BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
    Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
    Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pterostilbene Enhances TRAIL-Induced Apoptosis through the Induction of Death Receptors and Downregulation of Cell Survival Proteins in TRAIL-Resistance Triple Negative Breast Cancer Cells.
    Hung CM; Liu LC; Ho CT; Lin YC; Way TD
    J Agric Food Chem; 2017 Dec; 65(51):11179-11191. PubMed ID: 29164887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.